CTOs on the Move

Isoflex

www.isoflex.com

 
Isoflex is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.isoflex.com
  • PO BOX 29475
    San Francisco, CA USA 94129
  • Phone: 415.440.4433

Executives

Name Title Contact Details

Similar Companies

PharmSource Information Services

PharmSource Information Services is a Springfield, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OmniActive Health Technologies

OmniActive was born from Kancor Ingredients, an ingredient supplier rooted in the food and flavoring industry. Kancor has decades of experience extracting pure, quality ingredients from whole foods. With a history in extraction of natural products dating back to 1969, we at OmniActive are well versed in the technologies and processes necessary to provide specialized ingredients to the supplements space, as well as food and beverage companies. Kancor and OmniActive were both founded by the Mariwala family, with a long heritage in the spice industry. Patriarch Kanji Moorarji began trading in spices in 1857, an interest that continues to the present day. This history is reflected in the strength of our supply chain and raw material sourcing.

Solid Biosciences

Solid Biosciences (Solid) is a life science company singularly focused on solving Duchenne muscular dystrophy (Duchenne). We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with the expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive - attack the roots of the disease and improve daily life for patients. Solid is headquartered in Cambridge, MA, USA.

Sangamo

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.

bioMASON

We build with carbon the same way nature does. Our biocement® materials are healthier for us and the Planet.